Media Mentions
2007
David Gay was quoted in the Contra Costa Times on February 22 in an article on the ruling by the USPTO against Genentech in the re-examination of its patent that generates an estimated $300 million a year in royalties from companies using the technology to make cancer and rheumatoid arthritis treatments. "An earlier patent on the technology expired last year, and companies paying royalties expected to be able to stop," said Mr. Gay. "That's the idea that's upsetting people, and they are hoping the patent would go away," he said. "Somebody got heated up enough to say, 'I'm going to stop this,' and they filed the re-exam request."
David A. Gay Ph.D., Intellectual Property, Media & Technology, Litigation - IP, Media & Tech
David A. Gay, Ph.D. was quoted in the January 10 issue of The Baltimore Sun regarding the Supreme Court's decision on MedImmune patent case. Dr. Gay said the decision has the potential to restructure everything.
David A. Gay Ph.D., Intellectual Property, Media & Technology, Life Sciences & Medical Devices
2006
David Gay and client Glen Evans were featured in the August edition of IP Law & Business as a "dynamic duo." Mentioned in two articles, David and Glen's inventor-lawyer relationship was showcased highlighting the ingenuity of the attorney that allowed the inventor to reap maximum value from his ideas. The story discusses the biotech start-up founded by Glen Evans and David's role in ensuring that the intellectual property was in synch with the company's business goals. The company was sold to Johnson & Johnson in 2004 for millions of dollars.
David A. Gay Ph.D., Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
